Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q3 2020 · 10-Q
Revenue$573.00K$573.00K−55.4% vs Q3 2019 Net Income-$1.60M-$1.60MN/M vs Q3 2019 EPS Diluted-$0.04-$0.04N/M vs Q3 2019 Gross Profit$30,000−33.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,240,000N/M Free Cash Flowderived-$3,866,000N/M Margins · derivedGross margin5.2%+1.7 pt vs Q3 2019
Operating margin-292.8%−170.0 pt vs Q3 2019
Net margin-279.8%−190.4 pt vs Q3 2019
ended Dec 31, 2019 · filed Feb 10, 2020 · 41 d after period end